LIVMARLI (maralixibat)

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a commercial-stage biotech focused on developing transformative therapies for rare hepatic and metabolic diseases, with a core expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully launched its lead asset, LIVMARLI® (maralixibat), which is FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), marking a critical transition to a revenue-generating entity. Mirum's strategy leverages this commercial foundation to expand LIVMARLI's label into broader cholestatic indications and advance its pipeline, including brelovitug for chronic hepatitis delta virus (HDV), aiming to address significant unmet needs in rare disease communities. The company is led by an experienced team with deep expertise in rare disease drug development and commercialization.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a commercial-stage biotech focused on developing transformative therapies for rare hepatic and metabolic diseases, with a core expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully launched its lead asset, LIVMARLI® (maralixibat), which is FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), marking a critical transition to a revenue-generating entity. Mirum's strategy leverages this commercial foundation to expand LIVMARLI's label into broader cholestatic indications and advance its pipeline, including brelovitug for chronic hepatitis delta virus (HDV), aiming to address significant unmet needs in rare disease communities. The company is led by an experienced team with deep expertise in rare disease drug development and commercialization.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a commercial-stage biotech focused on developing transformative therapies for rare hepatic and metabolic diseases, with a core expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully launched its lead asset, LIVMARLI® (maralixibat), which is FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), marking a critical transition to a revenue-generating entity. Mirum's strategy leverages this commercial foundation to expand LIVMARLI's label into broader cholestatic indications and advance its pipeline, including brelovitug for chronic hepatitis delta virus (HDV), aiming to address significant unmet needs in rare disease communities. The company is led by an experienced team with deep expertise in rare disease drug development and commercialization.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a commercial-stage biotech focused on developing transformative therapies for rare hepatic and metabolic diseases, with a core expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully launched its lead asset, LIVMARLI® (maralixibat), which is FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), marking a critical transition to a revenue-generating entity. Mirum's strategy leverages this commercial foundation to expand LIVMARLI's label into broader cholestatic indications and advance its pipeline, including brelovitug for chronic hepatitis delta virus (HDV), aiming to address significant unmet needs in rare disease communities. The company is led by an experienced team with deep expertise in rare disease drug development and commercialization.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a commercial-stage biotech focused on developing transformative therapies for rare hepatic and metabolic diseases, with a core expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully launched its lead asset, LIVMARLI® (maralixibat), which is FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), marking a critical transition to a revenue-generating entity. Mirum's strategy leverages this commercial foundation to expand LIVMARLI's label into broader cholestatic indications and advance its pipeline, including brelovitug for chronic hepatitis delta virus (HDV), aiming to address significant unmet needs in rare disease communities. The company is led by an experienced team with deep expertise in rare disease drug development and commercialization.

Therapeutic Areas